Search
Zoetis Inc
ZTSAdd to Watchlist
76.810USD
+0.920+1.21%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
32.64BMarket Cap
12.71P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.21%
5 Days
-3.18%
1 Month
-5.55%
6 Months
-37.83%
Year to Date
-38.95%
1 Year
-51.18%
Key Figures
77.395Open
77.965High
5.86MVolume
12.71P/E TTM
10.74P/E Dynamic
2.060Dividend TTM
1.38%Turnover Ratio
75.890Prev. Close
76.315Low
243.69MTurnover
13.13P/E Static
9.80P/B
2.68%Div Yield TTM
18.07%ROA
172.23052wk High
0.70Volume Ratio
2.49BNet Profit
424.93MShares
6.0419EPS TTM
0.77Beta
67.01%ROE
72.38052wk Low
2.17%Amplitude
70.29%Gross Margin
32.64BMarket Cap
-4.20Reward/Risk
1.59%Risk Rate
TradingKey Stock Score of Zoetis Inc
Currency: USD Updated: 2026-06-22Key Insights
Zoetis Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 125.94.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zoetis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
42°C
Very Low
Very High
Negative
Zoetis Inc Highlights
StrengthsRisks
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.
Undervalued
The company’s latest PE is 12.56, at a low 3-year percentile range.
Held by Ruane Cunniff
Star Investor Ruane Cunniff holds 3.59M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.02.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
124.081
Target Price
+63.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zoetis Inc Info
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Ticker SymbolZTS
CompanyZoetis Inc
CEOPeck (Kristin C)
Websitehttps://www.zoetis.com/
Related Instruments
+0.54%
+3.37%
+2.60%
+2.07%
+3.54%
+2.98%
+0.66%
+3.33%
+0.14%
-1.44%
+0.32%
+1.53%
+2.59%
-0.36%
+2.58%
0.00%
+0.90%
+2.77%
-5.50%
+2.33%Popular Instruments
72.539
-0.406 (-0.56%)
294.300
-2.710 (-0.91%)
200.040
-8.610 (-4.13%)
4085.550
-25.200 (-0.61%)
670.750
-61.870 (-8.45%)
1961.070
-312.660 (-13.75%)
1051.770
-159.610 (-13.18%)
346.130
-3.550 (-1.02%)
62942.500
+501.800 (+0.80%)
381.610
-23.440 (-5.79%)
FAQs
What is the current price of Zoetis Inc (ZTS)?
The current price of Zoetis Inc (ZTS) is 76.81.
What is the symbol of Zoetis Inc?
The ticker symbol of Zoetis Inc is ZTS.
What is the 52-week high of Zoetis Inc?
The 52-week high of Zoetis Inc is 172.23.
What is the 52-week low of Zoetis Inc?
The 52-week low of Zoetis Inc is 72.38.
What is the market capitalization of Zoetis Inc?
The market capitalization of Zoetis Inc is 32.64B.
Is Zoetis Inc (ZTS) currently rated as Buy, Hold, or Sell?
According to analysts, Zoetis Inc (ZTS) has an overall rating of Buy, with a price target of 124.08.
What is the Earnings Per Share (EPS TTM) of Zoetis Inc (ZTS)?
The Earnings Per Share (EPS TTM) of Zoetis Inc (ZTS) is 6.03.
